Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
107,809,066
-
Total 13F shares
-
67,541,488
-
Share change
-
+2,614,563
-
Total reported value
-
$3,439,548,938
-
Put/Call ratio
-
138%
-
Price per share
-
$51.76
-
Number of holders
-
279
-
Value change
-
+$101,970,669
-
Number of buys
-
132
-
Number of sells
-
152
Institutional Holders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) as of Q2 2022
As of 30 Jun 2022,
Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) was held by
279 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
67,541,488 shares.
The largest 10 holders included
ARK Investment Management LLC, VANGUARD GROUP INC, BlackRock Inc., FMR LLC, STATE STREET CORP, Nikko Asset Management Americas, Inc., Sumitomo Mitsui Trust Holdings, Inc., VIKING GLOBAL INVESTORS LP, PRICE T ROWE ASSOCIATES INC /MD/, and ALLIANCEBERNSTEIN L.P..
This page lists
280
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.